CONNECTING AI & BT
PHARMACEUTICAL RESEARCH AND DEVELOPMENT FOR AGING-RELATED DISEASE
Our mission is to accelerate drug discovery and development by converging our ReBADD new artificial intelligence technology and anti-aging drug HTS technology. We will provide AI solution and aging therapeutics with constant innovation.
About us
Development of anti-aging treatment by removing senescent cells based on artificial intelligence
Due to the lack of molecular and biological mechanisms, anti-aging has been difficult to study. Recently, however, the mechanism by which senolysis can control senescent cells opens an entirely new era of anti-aging therapeutics.
We established the company to utilize research and technology related to the efficient control of senescent cells for the development of anti-aging treatments. Under the strategy that artificial intelligence (AI) technology is essential to create a new concept of drugs that has not existed, experts in the field of Biotechnology (BT) and AI founded the company. Major goal of company is to present a new paradigm for anti-aging drug development.
Currently, we (1) establish cell and animal models that can verify anti-aging target discovery technology, (2) use discovery platforms using artificial intelligence and semi high-throughput drug screening, and (3) develop anti-aging gene therapy. Through these technologies, the aim of company is to become a technology leader in the anti-aging industry by preventing or treating aging-related diseases, prolonging lifespan, and improving the quality of life for the elderly.
Main Strategy
• New drugs discovery with maximum binding power and chemical properties for target proteins
• Securing active substances based on high-efficiency drug candidate screening technology
• Verification of leading substance effects in cell and animal models
Team
Byung Ju Kim
CEO
Professional Experience: Director, Macrogen, Inc./Senior researcher, DGIST./Research staff member, SAIT Inc./Associate, Albert Einstein College of Medicine
Education: PhD in Biochemistry, The University of Ottawa Medical School
Chi Hyun Park
CTO
Current: Assistant Professor, Kangwon National University
Professional Experience: Postdoctoral fellows, Cleveland Clinic
/Staff Scientist, SAIT Inc./Senior researcher, KISTI
Education: PhD in Computer Science, Yonsei University
Advisory Board
Young-Sam Lee
Aging
Current: Associate Professor, DGIST
Education: PhD in Cell & Mol. Biology,
The University of Texas at Austin
Sang Hyun Park
AI
Current: Professor, Yonsei University
Education: PhD in Computer Science,
UCLA
Juyeon Kim
Business Development
Current: CEO, Binnobase
Education: EMBA in Life Science Management Program, HTW Berlin/Postdoc in Neuroinflammation, McGill University/PhD in Physiology, The University of Manchester
History
• 2023. 02. 28 Journal published at Computers in Biology and Medicine (IF: 6.698) (LINK)
• 2023. 01. 19 Journal published at Journal of Cheminformatics (15,8, IF: 8.489) (LINK)
• 2022. 12. 31 Journal published at Database Research (38(3): 47-61) (LINK)
• 2022. 12. 09 Journal published at Journal of Cheminformatics (14, 83, IF: 8.489) (LINK)
• 2022. 05. 23 Patent Registration (registration no. 10-2402582)
- Electronic Device That Generates Chemical Structural Formulas for New Drug Development Based on a Machine Learning-based Chemical Generation Model and the Operating Method Thereof
• 2021. 11. 08 Journal published at BMC Bioinformatics (22, 542, IF: 3.169) (LINK)
• 2021. 09. 02 Journal published at Experimental & Molecular Medicine (53:1092-1108, IF: 12.172) (LINK)
• 2021. 04. 01 Patent Registration (registration no. 10-2237189)
- Machine Learning based Protein-Ligand Binding Predictive Generation Apparatus for Drug Effect Estimation and Operation Method
• 2021. 03. 24 Certification of Venture Company by KIBO
• 2021. 02. 16 Certification of R&D Center
• 2020. 12. 01 Received Grants of TIPS Program (LINK)
• 2020. 07. 07 Established UBL Bio Corporation
Contact
E.mail: ublbio2020@gmail.com | Tel: 070-4647-3585 | Fax: 050-4207-8294
경기도 수원시 영통구 영통로 237, 211호 (신동, 에이스 하이엔드타워)
(237 Yeongtong-ro, Room 211, Yeongtong-gu, Suwon-si, 16679 South Korea)